Michael A. Wortley

TL;DR: XEN-D0501 (a potent TRPV1 antagonist) was compared with SB-705498 in preclinical studies to establish whether an improved efficacy profile would support a further clinical trial of XEN- D0501 in refractory chronic cough.

TL;DR: The absence of TRPV4-ATP-P2X3 interaction as a key osmosensing pathway involved in airway sensory nerve reflexes indicates a distinct neurobiology for this ion channel and implicates TRPv4 as a novel therapeutic target for neuronal hyperresponsiveness in the airways and symptoms, such as cough.

TL;DR: This study provides the first mechanistic insights into how exposure to urban air pollution leads to activation of guinea pig and human sensory nerves, which are responsible for respiratory symptoms.

TL;DR: For the first time, it is shown that tiotropium inhibits neuronal TRPV1-mediated effects through a mechanism unrelated to its anticholinergic activity.

TL;DR: It is shown that the DP1 receptor mediates sensory nerve activation in mouse, guinea pig and human vagal afferents and could be a therapeutic target for symptoms associated with asthma.